Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma

References

• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110(6):1713-22
   PubMed Web of Science ®Google Scholar
• Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the “red man”. Clin Dermatol 2005;23(2):206-17
   PubMedGoogle Scholar
• Sigurdsson VS, Toonstra J, Hezemans-Boer M, van Vloten WA. Erythroderma. Elsevier 1996;35(1):53-7
   Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. J Cutan Pathol 2005;32(10):647-74
   PubMedGoogle Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/sézary syndrome: validation of the revised international society for cutaneous lymphomas/european organisation for research and treatment of cancer staging proposal. J Clin Oncol 2010;28(31):4730-9
   PubMed Web of Science ®Google Scholar
• Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet 2008;371(9616):945-57
   PubMed Web of Science ®Google Scholar
• Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Dermatol 2011;64(2):352-404
   PubMed Web of Science ®Google Scholar
• Wieselthier JS, Koh HK. Sézary syndrome: diagnosis, prognosis, and critical review of treatment options. J Am Dermatol 1990;22(3):381-401
   PubMedGoogle Scholar
• Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. 1981;294(5838):268-71
   Google Scholar
• Yamaguchi T, Ohshima K, Karube K, et al. Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/lymphoma. Br J Dermatol 2005;152(1):76-81
   PubMedGoogle Scholar
• Cho-Vega JH, Tschen JA, Duvic M, Vega F. Early-stage mycosis fungoides variants: case-based review. Ann Diagn Pathol 2010;14(5):369-85
   PubMedGoogle Scholar
• Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126(10):2194-201
   PubMed Web of Science ®Google Scholar
• Ahern K, Gilmore ES. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol 2012;67(4):760-8
   PubMedGoogle Scholar
• Sampogna F, Frontani M, Baliva G, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol 2009;160(4):815-22
   PubMed Web of Science ®Google Scholar
• Pujol RM, Gallardo F, Llistosella E, et al. Invisible mycosis fungoides: a diagnostic challenge. J Am Acad Dermatol 2002;47(2):S168-71
   PubMedGoogle Scholar
• Green SB, Byar DP, Lamberg SI. Prognostic variables in mycosis fungoides. Cancer 1981;47(11):2671-7
   PubMedGoogle Scholar
• Martin SJ, Duvic M. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome. Int J Dermatol 2012;51(10):1195-8
   PubMedGoogle Scholar
• Gathers RC, Scherschun L, Malick F, et al. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol 2002;47(2):191-7
   PubMedGoogle Scholar
• Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991;78(12):3269-74
   PubMed Web of Science ®Google Scholar
• Vonderheid EC. On the diagnosis of erythrodermic cutaneous T cell lymphoma. J Cutaneous Pathology 2006;33(s1):27-42
   PubMedGoogle Scholar
• Trotter MJ, Whittaker SJ, Orchard GE, Smith NP. Cutaneous histopathology of Sézary syndrome: a study of 41 cases with a proven circulating T cell clone. J Cutan Pathol 1997;24(5):286-91
   PubMedGoogle Scholar
• Bittencourt AL, Barbosa HS, Vieira MD, Farré L. Adult T-cell leukemia/lymphoma (ATL) presenting in the skin: clinical, histological and immunohistochemical features of 52 cases. Acta Oncol 2009;48(4):598-604
   PubMed Web of Science ®Google Scholar
• Mallett RB, Matutes E, Catovsky D, et al. Cutaneous infiltration in T-cell prolymphocytic leukaemia. Br J Dermatol 1995;132(2):263-6
   PubMed Web of Science ®Google Scholar
• Jones CL, Ferreira S, McKenzie RCT, et al. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma. J Invest Dermatol 2012;132(8):2042-9
   PubMed Web of Science ®Google Scholar
• Russell Jones R, Whittaker S. T-cell receptor gene analysis in the diagnosis of Sézary syndrome. J Am Dermatol 1999;41(2 Pt 1):254-9
   PubMedGoogle Scholar
• Juarez T, Isenhath SN, Polissar NL, et al. Analysis of T-cell receptor gene rearrangement for predicting clinical outcome in patients with cutaneous T-cell lymphoma: a comparison of southern blot and polymerase chain reaction methods. Arch Dermatol 2005;141(9):1107-13
   PubMedGoogle Scholar
• Dearden C. How I treat prolymphocytic leukemia. Blood 2012;120(3):538-51
   PubMed Web of Science ®Google Scholar
• Humme D, Lukowsky A, Gierisch M, et al. T-cell receptor gene rearrangement analysis of sequential biopsies in cutaneous T-cell lymphomas with the Biomed-2 PCR reveals transient T-cell clones in addition to the tumor clone. Exp Dermatol 2014;23(7):504-8
   PubMedGoogle Scholar
• Robinson MA. Usage of human T-cell receptor Vβ, Jβ, Cβ, and Vα gene segments is not proportional to gene number. Hum Immunol 1992;35(1):60-7
   PubMedGoogle Scholar
• Vermeer MH, van Doorn R, Dijkman R, et al. Novel and highly recurrent chromosomal alterations in Sézary syndrome. Cancer Res 2008;68(8):2689-98
   PubMedGoogle Scholar
• Marti RM, Pujol RM, Servitje O, et al. Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma 2003;44(1):59-69
   PubMed Web of Science ®Google Scholar
• Tsai EY, Taur A, Espinosa L, et al. Staging accuracy in mycosis fungoides and Sézary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 2006;142(5):577-84
   PubMedGoogle Scholar
• Kuo PH, McClennan BL, Carlson K, et al. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imaging Biol 2008;10(2):74-81
   PubMedGoogle Scholar
• Burke JS, Colby TV. Dermatopathic lymphadenopathy. Comparison of cases associated and unassociated with mycosis fungoides. Am J Surg Pathol 1981;5(4):343-52
   PubMedGoogle Scholar
• Sausville EA, Worsham GF, Matthews MJ, et al. Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 1985;16(11):1098-109
   PubMedGoogle Scholar
• Vonderheid EC, Diamond LW, van Vloten WA, et al. Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the working formulation of non-Hodgkin’s lymphomas for clinical usage. Cancer 1994;73(1):207-18
   PubMedGoogle Scholar
• Wong HK. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma. Discov Med 2013;16(87):71-8
   PubMedGoogle Scholar
• Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for cutaneous lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011;29(18):2598-607
   PubMed Web of Science ®Google Scholar
• Stevens SR, Ke MS, Parry EJ, et al. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol 2002;138(1):42-8
   PubMedGoogle Scholar
• Olsen EA, Kim YH, Kuzel TM, et al.et al. Multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(21):3109-15
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Morris S. How big is your hand and should you use it to score skin in cutaneous T-cell lymphoma? Br J Dermatol 2013;169(2):260-5
   PubMed Web of Science ®Google Scholar
• van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136(4):504-10
   PubMedGoogle Scholar
• Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome. Arch Dermatol 2003;139:7
   Google Scholar
• Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer 2013;49(13):2859-68
   PubMed Web of Science ®Google Scholar
• Demierre M-F, Olsen EA, Williams CA, et al. An In-Depth Assessment of the Impact of Pruritus on Health-Related Quality of Life of Patients with Mycosis Fungoides/Sézary Syndrome. J Support Oncol 2011;9(3):e13-19
   PubMedGoogle Scholar
• Beynon T, Radcliffe E, Child F, et al. What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence. Br J Dermatol 2014;170(3):599-608
   PubMed Web of Science ®Google Scholar
• Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006;42(8):1014-30
   PubMed Web of Science ®Google Scholar
• Ponte P, Serrão V, Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatol Venereol 2009;24(6):716-21
   PubMedGoogle Scholar
• Whittaker S, Ortiz P, Dummer R, et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00. Br J Dermatol 2012;167(3):678-87
   PubMed Web of Science ®Google Scholar
• Papadavid E, Antoniou C, Nikolaou V, et al. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides. Am J Clin Dermatol 2008.9(3):169-73
   PubMed Web of Science ®Google Scholar
• Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell. Am Soc Hematol 1999;93(8):2753. Available from: http://bloodjournal.hematologylibrary.org/content/93/8/2753.2.abstract
   Google Scholar
• Nikolaou V, Siakantaris MP, Vassilakopoulos TP, et al. PUVA plus interferon α2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series. J Eur Acad Dermatol Venereol 2011;25(3):354-7
   PubMed Web of Science ®Google Scholar
• Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ. Low-dose palliative radiotherapy for cutaneous B-and T-cell lymphomas. Int J Radiat Oncol Biol Phys 2009;74(1):154-8
   PubMedGoogle Scholar
• Sawyer EJ, Timothy AR. Low dose palliative radiotherapy in low grade non-Hodgkin’s lymphoma. Radiother Oncol 1997;42(1):49-51
   PubMedGoogle Scholar
• Stein M, Farrar N, Jones GW, et al. Central neurologic involvement in mycosis fungoides: ten cases, actuarial risk assessment, and predictive factors. Cancer J 2006;12(1):55-62
   PubMed Web of Science ®Google Scholar
• Harrison C, Young J, Navi D, et al. Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 2012;81(4):e651-7
   Google Scholar
• Morris SL, McGovern M, Bayne S, et al. Results of a 5-week schedule of modern total skin electron beam radiation therapy. Int J Radiat Oncol Biol Phys 2013;86(5):936-41
   PubMed Web of Science ®Google Scholar
• Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002;47(3):364-70
   PubMed Web of Science ®Google Scholar
• Kaye FJ, Bunn PA, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321(26):1784-90
   PubMed Web of Science ®Google Scholar
• Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sézary syndrome. J Clin Oncol 2010;28(14):2365-72
   PubMed Web of Science ®Google Scholar
• Kohn EC, Steis RG, Sausville EA, et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome. J Clin Oncol 1990;8(1):155-60
   PubMed Web of Science ®Google Scholar
• Bunn PA, Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986;57(8 Suppl):1689-95
   PubMed Web of Science ®Google Scholar
• Straus DJ, Duvic M, Kuzel T, et al. Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007;109(9):1799-803
   PubMed Web of Science ®Google Scholar
• Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002;47(5):672-84
   PubMedGoogle Scholar
• Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral Bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-Cell lymphoma. Arch Dermatol 2001;137(5):581-93
   PubMedGoogle Scholar
• Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol 2009;160(6):1299-307
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Morris S, Azurdia R, et al. UK consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 2013;168(1):192-200
   PubMed Web of Science ®Google Scholar
• Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19(2):376-88
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Saleh MN, Kuzel TM. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2. Blood 1998;91(2):399-405
   PubMed Web of Science ®Google Scholar
• Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005;106(2):454-7
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003;101(11):4267-72
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol 2003;71(4):250-6
   PubMed Web of Science ®Google Scholar
• Alinari L, Geskin L, Grady T, et al. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly. Leukemia Res 2008;32(8):1299-303
   PubMed Web of Science ®Google Scholar
• Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 2009;50(12):1969-76
   PubMed Web of Science ®Google Scholar
• Bernengo M-G, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007;92(6):784-94
   PubMed Web of Science ®Google Scholar
• Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109(11):4655-62
   PubMed Web of Science ®Google Scholar
• Ogura M, Ishida T, Hatake K, et al.et al. Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 antibody, in patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. J Clin Oncol 2014;32(11):1157-63
   PubMed Web of Science ®Google Scholar
• Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987;316(6):297-303
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Taylor P, Holtick U, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008;158(4):659-78
   PubMedGoogle Scholar
• Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apher Sci 2003;28(1):81-9
   PubMedGoogle Scholar
• Russell Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 2000;142(1):16-21
   PubMed Web of Science ®Google Scholar
• Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Dermatol 1996;35(4):573-9
   PubMedGoogle Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31-9
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410-17
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, et al. Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. J Clin Oncol 2010;28(29):4485-91
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Tani M, et al.et al. Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. J Clin Oncol 2007;25(27):4293-7
   PubMed Web of Science ®Google Scholar
• Bunn PA, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994;121(8):592-602
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012;119(18):4115-22
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rosen ST, Guitart J, et al. Multicenter phase II trial of temozolomide in mycosis fungoides/Sézary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res 2011;17(17):5748-54
   PubMed Web of Science ®Google Scholar
• Illidge T, Chan C, Counsell N, et al. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. Nature 2013;109(10):2566-73
   Google Scholar
• Akpek G, Koh HK, Bogen S, et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999;86(7):1368-76
   PubMed Web of Science ®Google Scholar
• Fierro MT, Doveil GC, Quaglino P, et al. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma. Dermatology (Basel) 1997;194(3):268-72
   PubMedGoogle Scholar
• Ingen-Housz-Oro S, Bachelez H, Verola O, et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transplant 2004;33(6):629-34
   PubMedGoogle Scholar
• Olavarria E, Child F, Woolford A. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001;114(3):624-31. Available from: http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.02919.x/full
   PubMedGoogle Scholar
• Duarte RF, Canals C, Onida F, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2010;28(29):4492-9
   PubMed Web of Science ®Google Scholar
• Molina A. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory sezary syndrome and mycosis fungoides. J Clin Oncol 2005;23(25):6163-71
   PubMedGoogle Scholar
• Masood N, Russell KJ, Olerud JE, et al. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 2002;47(1):140-5
   PubMedGoogle Scholar
• Guitart J, Wickless SC, Oyama Y. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 2002;138(10):1359-65
   PubMed Web of Science ®Google Scholar
• Delioukina M, Zain J, Palmer JM, et al. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine–melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplantation 2011;47(1):65-72
   PubMedGoogle Scholar
• Ralfkiaer U, Hagedorn PH, Bangsgaard N, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011;118(22):5891-900
   PubMed Web of Science ®Google Scholar
• Marstrand T, Ahler CB, Ralfkiaer U, et al. Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas. Leuk Lymphoma 2014;55(4):957-8
   PubMed Web of Science ®Google Scholar
• Wysocka M, Kossenkov AV, Benoit BM, et al. CD164 and FCRL3 are highly expressed on CD4+ CD26- T Cells in Sézary Syndrome Patients. Nature 2013;134(1):229-36
   Google Scholar
• Kamstrup MR, Lindahl LM, Gniadecki R, et al. Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. Br J Dermatol 2012;166(2):399-404
   PubMedGoogle Scholar
• Chiarion-Sileni V, Bononi A, Fornasa CV, et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 2002;95(3):569-75
   PubMed Web of Science ®Google Scholar
• Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukindiftitox for patients with cutaneous T-cell lymphoma. J ClinOncol 2010;28(11):1870-7
   PubMed Web of Science ®Google Scholar
• Cummings FJ, Kim K, Neiman RS, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J ClinOncol 1991;9(4):565-71
   PubMedGoogle Scholar
• Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999;17(10):3117-21
   PubMedGoogle Scholar
• Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology 2000;14:37-40
   PubMedGoogle Scholar
• Foss FM, Ihde DC, Breneman DL, et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 1992;10:1907-13
   PubMed Web of Science ®Google Scholar
• Ho AD, Suciu S, Stryckmans P, et al. Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group. Ann.Oncol 1999;10:1493-8
   PubMed Web of Science ®Google Scholar
• Kuzel TM, Hurria A, Samuelson E, et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996;87:906-11
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18:2603-6
   PubMed Web of Science ®Google Scholar
• Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005;104:2437-41
   PubMed Web of Science ®Google Scholar
• Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996;34:626-31
   PubMed Web of Science ®Google Scholar
• Winkelmann RK, Diaz-Perez JL, Buechner SA. The treatment of Sezary Syndrome. J Am AcadDermatol 1984;10(6):1000-4
   PubMedGoogle Scholar